Mehdi Dehghani1, Pedram Keshavarz2, Abdolrasoul Talei3, Majid Akrami3, Sedighe Tahmasebi3, Akbar Safaie4, Maryam Ghanbari5. 1. Hematology Research Center, Department of Hematology and Medical oncology, Shiraz University of Medical Sciences, Shiraz, Iran. 2. Department of Radiology, Medical Imaging Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 3. Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran. 4. Department of Pathology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran. 5. Department of Internal Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.
Abstract
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer (BC), and its diagnosis is associated with negative expression of hormone receptors and HER2/neu. It consists of 10-20% of all BCs diagnosed. METHODS AND MATERIALS: This study focuses on three groups with different pathology: group one showed complete triple-negative HER2 expression with IHC of BC; groups two and three included patients with ER-, PR-, and HER21+, and ER-, PR-, and HER22+ with a negative FISH test. These three groups were compared from the point of prognosis, which consisted of tumor size, patients' age, lymphatic, vascular and perineural invasion, organ metastasis, number of lymph nodes involvement, and the survival rate. RESULTS: A total of 459 TNBC patients were enrolled, of which 268 were placed in the HER20 group, 146 in the HER21+ group, and 45 in the HER22+ group. Distant metastasis and recurrence rate were more common in HER20 patients, but bone metastasis was more common in patients with low HER2 expression. All patients with HER20 had a smaller tumor size at the time of BC diagnosis in comparison to patients in the low HER2 expression group. Patients with HER22+ had less lymphatic and vascular invasion as well as axillary lymph nodes involvement, but larger tumor size at presentation, resulting in a lower rate of recurrence and higher overall survival. CONCLUSION: The findings revealed that patients with HER22+ had better outcome in comparison to the patients with HER20 and HER21+. Furthermore, the results showed that many patients with HER22+ expression were not basal-like and had good prognosis amongst TNBC patients.
BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive type of breast cancer (BC), and its diagnosis is associated with negative expression of hormone receptors and HER2/neu. It consists of 10-20% of all BCs diagnosed. METHODS AND MATERIALS: This study focuses on three groups with different pathology: group one showed complete triple-negative HER2 expression with IHC of BC; groups two and three included patients with ER-, PR-, and HER21+, and ER-, PR-, and HER22+ with a negative FISH test. These three groups were compared from the point of prognosis, which consisted of tumor size, patients' age, lymphatic, vascular and perineural invasion, organ metastasis, number of lymph nodes involvement, and the survival rate. RESULTS: A total of 459 TNBC patients were enrolled, of which 268 were placed in the HER20 group, 146 in the HER21+ group, and 45 in the HER22+ group. Distant metastasis and recurrence rate were more common in HER20 patients, but bone metastasis was more common in patients with low HER2 expression. All patients with HER20 had a smaller tumor size at the time of BC diagnosis in comparison to patients in the low HER2 expression group. Patients with HER22+ had less lymphatic and vascular invasion as well as axillary lymph nodes involvement, but larger tumor size at presentation, resulting in a lower rate of recurrence and higher overall survival. CONCLUSION: The findings revealed that patients with HER22+ had better outcome in comparison to the patients with HER20 and HER21+. Furthermore, the results showed that many patients with HER22+ expression were not basal-like and had good prognosis amongst TNBC patients.
Entities:
Keywords:
Basal-like tumor; Her2/neu; Triple-negative breast cancer; hormone receptor
Authors: Carol E DeSantis; Stacey A Fedewa; Ann Goding Sauer; Joan L Kramer; Robert A Smith; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-10-29 Impact factor: 508.702
Authors: Surabhi Amar; Ann E McCullough; Winston Tan; Xochiquetzal J Geiger; Judy C Boughey; Rebecca B McNeil; Kyle E Coppola; Sarah A McLaughlin; Frances M Palmieri; Edith A Perez Journal: Oncologist Date: 2010-10-07
Authors: Betul Bolat Kucukzeybek; Ibrahım V Bayoglu; Yuksel Kucukzeybek; Yasar Yıldız; Utku Oflazoglu; Murat K Atahan; Halıl Taskaynatan; Ahmet Alacacioglu; Seyran Yigit; Mustafa O Tarhan Journal: Pol J Pathol Date: 2018 Impact factor: 1.072
Authors: Cameron N Johnstone; Andrew D Pattison; Paul F Harrison; David R Powell; Peter Lock; Matthias Ernst; Robin L Anderson; Traude H Beilharz Journal: Int J Cancer Date: 2020-02-24 Impact factor: 7.396
Authors: A S Noman; M Uddin; M Z Rahman; M J Nayeem; S S Alam; Z Khatun; M Wahiduzzaman; A Sultana; M L Rahman; M Y Ali; D Barua; I Ahmed; M S Islam; A Aboussekhra; H Yeger; W A Farhat; S S Islam Journal: Sci Rep Date: 2016-01-05 Impact factor: 4.379